News for Mabpharm Limited (2181.HK)

NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited (2181.HK), has recently received approval from the China National Medical Administration (NMPA) for marketing. Enlituo® is indicated for use in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).

The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcoming therapies and is...

Chronic Refractory Cough Market to Observe Stupendous Growth by 2032, Assesses DelveInsight | Key Players to Watch Out - Merck, Kyorin, NeRRe, Bellus...

/PRNewswire/ -- DelveInsight's 'Asthma Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline asthma...

Visiongain has published a new report entitled Respiratory Inhalers 2023-2033. It includes profiles of Respiratory Inhalers and Forecasts Market Segment by...

Visiongain has published a new report entitled Respiratory Inhalers 2023-2033. It includes profiles of Respiratory Inhalers and Forecasts Market Segment by...